☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Iovance Biotherapeutics
The US FDA Puts Clinical Hold on Iovance Biotherapeutics’ (IOV-LUN-202) Trial of LN-145 for Non-Small Cell Lung Cancer
January 1, 2024
Iovance Biotherapeutics Reports the First Patient Randomizing of Lifileucel in P-III Trial (TILVANCE-301) for Frontline Advanced M...
June 15, 2023
Iovance Biotherapeutics Reports the US FDA Acceptance of BLA for Lifileucel to Treat Advanced Melanoma
May 30, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.